Intermittent PD-1/PD-L1 ICI + VEGFR-TKI
2025DZKY-069-01
Phase 2 small_molecule active
Quick answer
Intermittent PD-1/PD-L1 ICI + VEGFR-TKI for Renal Cell Carcinoma (RCC) is a Phase 2 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- Renal Cell Carcinoma (RCC)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active